c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,869 · see citing works

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Flaherty, K. T., Puzanov, I. J., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,542 · see citing works

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330 · see citing works

RAS oncogenes: the first 30 years

Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902 · see citing works

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Bollag, G. E., Hirth, P., Tsai, J. Y., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W. R., Zhang, C., Zhang, Y., Habets, G. G. M., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,837 · see citing works

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,818 · see citing works

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,614 · see citing works

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

Heidorn, S. J., Milagre, C. S., Whittaker, S. R., Nourry, A., Niculescu‐Duvaz, I., Dhomen, N. S., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C. A., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,468 · see citing works

Ras oncogenes: split personalities

Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · see citing works

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346 · see citing works

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330 · see citing works

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1819 · Cited by 1,267 · see citing works

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga‐Kalabis, M., Cipolla, A. K., Wubbenhorst, B. S., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,250 · see citing works

Somatic activation of the K-ras oncogene causes early onset lung cancer in mice

Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179 · see citing works

A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017 · see citing works

MAP kinase kinase kinase, MAP kinase kinase and MAP kinase

Marshall, C. J. (1994) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(94)90095-7 · Cited by 1,005 · see citing works

The Ink4/Arf locus is a barrier for iPS cell reprogramming

Li, H., Collado, M., Villasante, A., Strati, K., Ortega, S., Cañamero, M., Blasco, M. A., & Serrano, M. (2009) · Nature · doi:10.1038/nature08290 · Cited by 968 · see citing works

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841 · see citing works

Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects

Tuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798 · see citing works

Association of KRAS p.G13D Mutation with Outcome in Patients with Chemotherapy-Refractory Metastatic Colorectal Cancer Treated with Cetuximab

De Roock, W., Jonker, D. J., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., et al. (2010) · JAMA · doi:10.1001/jama.2010.1535 · Cited by 748 · see citing works

Defective Thymocyte Maturation in p44 MAP Kinase (Erk 1) Knockout Mice

Pagès, G., Guérin, S., Grall, D., Bonino, F., Smith, A., Anjuere, F., Auberger, P., & Pouysségur, J. (1999) · Science · doi:10.1126/science.286.5443.1374 · Cited by 654 · see citing works

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer

Rinehart, J., Adjei, A. A., LoRusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.185 · Cited by 645 · see citing works

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon

Haigis, K. M., Kendall, K. R., Wang, Y., Cheung, A., Haigis, M. C., Glickman, J. N., Niwa-Kawakita, M., Sweet-Cordero, A., Sebolt-Leopold, J., Shannon, K. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.115 · Cited by 610 · see citing works

Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context

Guerra, C. E., Mijimolle, N., Dhawahir, A., Dubus, P. R., Barradas, M., Serrano, M., Campuzano, V., & Barbacid, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00191-0 · Cited by 566 · see citing works

Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice.

Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y.-H., Warne, P., Nicke, B., Nye, E., Stamp, G., Alitalo, K., & Downward, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.051 · Cited by 553 · see citing works

The Differential Effects of Mutant <i>p53</i> Alleles on Advanced Murine Lung Cancer

Jackson, E. L., Olive, K. P., Tuveson, D. A., Bronson, R., Crowley, D., Brown, M., & Jacks, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2193 · Cited by 553 · see citing works

Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma

Meylan, E., Dooley, A. L., Feldser, D. M., Shen, L., Turk, E., Ouyang, C., & Jacks, T. (2009) · Nature · doi:10.1038/nature08462 · Cited by 514 · see citing works

RASSF1A Elicits Apoptosis through an MST2 Pathway Directing Proapoptotic Transcription by the p73 Tumor Suppressor Protein

Matallanas, D., Romano, D., Yee, K. S. Y., Meissl, K., Kučerová, L., Piazzolla, D., Baccarini, M., Vass, J. K., Kölch, W., & O’Neill, E. E. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.08.008 · Cited by 416 · see citing works

A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma

Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415 · see citing works

Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta

Giroux, S., Tremblay, M. G., Bernard, D., Cardin-Girard, J.-F., Aubry, S., Larouche, L., Rousseau, S., Huot, J. L., Landry, J., Jeannotte, L., et al. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80164-x · Cited by 342 · see citing works

The Role of Erk1 and Erk2 in Multiple Stages of T Cell Development

Fischer, A. M., Katayama, C. D., Pagès, G., Pouysségur, J., & Hedrick, S. Μ. (2005) · Immunity · doi:10.1016/j.immuni.2005.08.013 · Cited by 330 · see citing works

Embryonic lethality and fetal liver apoptosis in mice lacking the c‐raf‐1 gene

Mikula, M., Schreiber, M., Husak, Z., Kučerová, L., Rüth, J., Wieser, R., Zatloukal, K., Beug, H., Wagner, E. F., & Baccarini, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.8.1952 · Cited by 311 · see citing works

In Melanoma, RAS Mutations Are Accompanied by Switching Signaling from BRAF to CRAF and Disrupted Cyclic AMP Signaling

Dumaz, N., Hayward, R., Martin, J., Ogilvie, L. M., Hedley, D., Curtin, J. A., Bastian, B. C., Springer, C. J., & Marais, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4227 · Cited by 304 · see citing works

Four Human Ras Homologs Differ in Their Abilities to Activate Raf-1, Induce Transformation, and Stimulate Cell Motility

Voice, J. K., Klemke, R. L., Le, A., & Jackson, J. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17164 · Cited by 288 · see citing works

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

Haura, E. B., Ricart, A. D., Larson, T. G., Stella, P. J., Bazhenova, L., Miller, V. A., Cohen, R. B., Eisenberg, P. D., Selaru, P., Wilner, K. D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1920 · Cited by 237 · see citing works

Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis

Yamaguchi, O., Watanabe, T., Nishida, K., Kashiwase, K., Higuchi, Y., Takeda, T., Hikoso, S., Hirotani, S., Asahi, M., Taniike, M., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20317 · Cited by 204 · see citing works

A Mek1–Mek2 heterodimer determines the strength and duration of the Erk signal

Catalanotti, F., Reyes, G. X., Jesenberger, V., Galabova‐Kovacs, G., Simoes, R. D. M., Carugo, O., & Baccarini, M. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1564 · Cited by 182 · see citing works

Mek2 Is Dispensable for Mouse Growth and Development

Bélanger, L.-F., Roy, S., Tremblay, M. G., Brott, B. K., Steff, A., Mourad, W. M., Hugo, P., Erikson, R. L., & Charron, J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.14.4778-4787.2003 · Cited by 181 · see citing works

Role of Rho-family proteins in cell adhesion and cancer

Malliri, A., & Collard, J. G. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00098-x · Cited by 173 · see citing works

A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens

Hainsworth, J. D., Cebotaru, C. L., Kanarev, V., Ciuleanu, T., Damyanov, D., Stella, P. J., Ganchev, H., Pover, G. M., Morris, C. D., & Tzekova, V. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e8b3a3 · Cited by 162 · see citing works

Ral GTPases: corrupting the exocyst in cancer cells

Camonis, J., & White, M. A. (2005) · Trends in Cell Biology · doi:10.1016/j.tcb.2005.04.002 · Cited by 115 · see citing works

Raf-1 Addiction in Ras-Induced Skin Carcinogenesis

Ehrenreiter, K., Kern, F., Velamoor, V., Meissl, K., Galabova‐Kovacs, G., Sibilia, M. C., & Baccarini, M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.008 · Cited by 106 · see citing works

Sorafenib Inhibits Non–Small Cell Lung Cancer Cell Growth by Targeting B-RAF in KRAS Wild-Type Cells and C-RAF in KRAS Mutant Cells

Takezawa, K., Okamoto, I., Yonesaka, K., Hatashita, E., Yamada, Y., Fukuoka, M., & Nakagawa, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1076 · Cited by 91 · see citing works

Adenoviral Augmentation of Elafin Protects the Lung Against Acute Injury Mediated by Activated Neutrophils and Bacterial Infection

Simpson, A. J., Wallace, W. A., Marsden, M. E., Govan, J. R. W., Porteous, D. J., Haslett, C., & Sallenave, J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1778 · Cited by 89 · see citing works

ERK and Beyond: Insights from B-Raf and Raf-1 Conditional Knockouts

Galabova‐Kovacs, G., Kolbus, A., Matzen, D., Meiss, K., Piazzolla, D., Rubiolo, C., Steinitz, K. N., & Baccarini, M. (2006) · Cell Cycle · doi:10.4161/cc.5.14.2981 · Cited by 88 · see citing works

Raf-1 sets the threshold of Fas sensitivity by modulating Rok-α signaling

Piazzolla, D., Meissl, K., Kučerová, L., Rubiolo, C., & Baccarini, M. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200504137 · Cited by 84 · see citing works

Requirement forMap2k1(Mek1) in extra-embryonic ectoderm during placentogenesis

Bissonauth, V., Roy, S., Gravel, M., Guillemette, S., & Charron, J. (2006) · Development · doi:10.1242/dev.02526 · Cited by 80 · see citing works

Forebrain-specific knockout of B-raf kinase leads to deficits in hippocampal long-term potentiation, learning, and memory

Chen, A. P., Ohno, M., Giese, K.-P., Kühn, R., Chen, R. L., & Silva, A. J. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20703 · Cited by 77 · see citing works

Protective Role of Raf-1 in Salmonella-Induced Macrophage Apoptosis

Jesenberger, V., Procyk, K. J., Rüth, J., Schreiber, M., Theussl, H., Wagner, E. F., & Baccarini, M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.3.353 · Cited by 63 · see citing works

Selective Role for Mek1 but not Mek2 in the Induction of Epidermal Neoplasia

Scholl, F. A., Dumesic, P. A., Barragan, D. I., Harada, K., Charron, J., & Khavari, P. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1963 · Cited by 53 · see citing works

From autoinhibition to inhibition in trans: the Raf-1 regulatory domain inhibits Rok-α kinase activity

Niault, T., Sobczak, I., Meissl, K., Weitsman, G. E., Piazzolla, D., Maurer, G., Kern, F., Ehrenreiter, K., Hamerl, M., Moarefi, I., et al. (2009) · The Journal of Cell Biology · doi:10.1083/jcb.200906178 · Cited by 52 · see citing works

Drugging the undruggable RAS: Mission Possible?

Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · see citing works

Non-small-cell lung cancers: a heterogeneous set of diseases

Chen, Z., Brainson, C. F., Hammerman, P. S., Kim, C. F., & Wong, K. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3775 · Cited by 1,973 · see citing works

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer

Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875 · see citing works

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

Holderfield, M. T., Deuker, M. M., McCormick, F. P., & McMahon, M. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3760 · Cited by 828 · see citing works

Dragging ras back in the ring

Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · see citing works

Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening

McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658 · see citing works

Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras

Wang, T., Yu, H., Hughes, N. W., Liu, B., Kendirli, A., Klein, K., Chen, W. W., Lander, E. S., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.01.013 · Cited by 632 · see citing works

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road

Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606 · see citing works

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

Degirmenci, U., Wang, M., & Hu, J. (2020) · Cells · doi:10.3390/cells9010198 · Cited by 541 · see citing works

Genetics and biology of pancreatic ductal adenocarcinoma

Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes &amp; Development · doi:10.1101/gad.275776.115 · Cited by 527 · see citing works

Targeting the MAPK pathway in KRAS-driven tumors

Drosten, M., & Barbacid, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.013 · Cited by 512 · see citing works

Oncogenic KRAS signalling in pancreatic cancer

EŞER, S., Schnieke, A., Schneider, G., & Saur, D. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.215 · Cited by 506 · see citing works

Therapeutic strategies to target RAS-mutant cancers

Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420 · see citing works

Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase

Ruess, D. A., Heynen, G. J., Ciecielski, K. J., Ai, J., Berninger, A., Kabacaoglu, D., Görgülü, K., Dantes, Z., Wörmann, S. M., Diakopoulos, K. N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0024-8 · Cited by 370 · see citing works

Downstream of Mutant KRAS, the Transcription Regulator YAP Is Essential for Neoplastic Progression to Pancreatic Ductal Adenocarcinoma

Zhang, W., Nandakumar, N., Shi, Y., Manzano, M., Smith, A., Graham, G., Gupta, S., Vietsch, E. E., Laughlin, S. Z., Wadhwa, M., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2005049 · Cited by 360 · see citing works

Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer

Eser, S., Reiff, N., Messer, M., Seidler, B., Gottschalk, K., Dobler, M., Hieber, M., Arbeiter, A., Klein, S., Kong, B., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.023 · Cited by 360 · see citing works

Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors

Lito, P., Saborowski, A., Yue, J., Solomon, M., Joseph, E., Gadal, S., Saborowski, M., Kastenhuber, E., Fellmann, C., Ohara, K., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.011 · Cited by 324 · see citing works

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

Hatzivassiliou, G., Haling, J. R., Chen, H., Song, K. W., Price, S., Heald, R. A., Hewitt, J. F. M., Zak, M., Peck, A., Orr, C., et al. (2013) · Nature · doi:10.1038/nature12441 · Cited by 317 · see citing works

Tissue-specific tumorigenesis: context matters

Schneider, G., Schmidt‐Supprian, M., Rad, R., & Saur, D. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.5 · Cited by 323 · see citing works

KRAS-Mutant non-small cell lung cancer: From biology to therapy

Ferrer, I., Zugazagoitia, J., Herbertz, S., John, W. J., Paz-Ares, L. G., & Schmid‐Bindert, G. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.013 · Cited by 306 · see citing works

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target

Román, M., Baraibar, I., López, I., Nadal, E., Rolfo, C., Vicent, S., & Gil-Bazo, I. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0789-x · Cited by 301 · see citing works

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Peng, S.-B., Henry, J. R., Kaufman, M. D., Lu, W.-P., Smith, B. D., Vogeti, S., Rutkoski, T. J., Wise, S., Chun, L., Zhang, Y., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.002 · Cited by 297 · see citing works

ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?

Buscà, R., Pouysségur, J., & Lenormand, P. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00053 · Cited by 283 · see citing works

The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer

Kumar, M. S., Hancock, D. C., Molina‐Arcas, M., Steckel, M., East, P., Diefenbacher, M. E., Armenteros-Monterroso, E., Lassailly, F., Matthews, N., Nye, E. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.059 · Cited by 264 · see citing works

The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry

Kahrilas, P. J., & Boeckxstaens, G. E. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 236 · see citing works

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer

Socinski, M. A., Goldman, J. W., El‐Hariry, I. A., Koczywas, M., Vukovic, V., Horn, L., Paschold, E., Salgia, R., West, H., Sequist, L. V. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3381 · Cited by 214 · see citing works

ERKs in Cancer: Friends or Foes?

Deschênes‐Simard, X., Kottakis, F., Meloche, S., & Ferbeyre, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2381 · Cited by 217 · see citing works

Simple and Rapid In Vivo Generation of Chromosomal Rearrangements using CRISPR/Cas9 Technology

Blasco, R. B., Karaca, E., Ambrogio, C., Cheong, T.-C., Karayol, E., Minero, V. G., Voena, C., & Chiarle, R. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.051 · Cited by 206 · see citing works

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes

Hunter, S. M., Chenevix‐Trench, G., Anglesio, M. S., Ryland, G. L., Sharma, R. N., Chiew, Y.-E., Rowley, S. M., Doyle, M., Li, J., Gilks, C. B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5438 · Cited by 204 · see citing works

Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity

Ishii, N., Harada, N., Joseph, E. W., Ohara, K., Miura, T., Sakamoto, H., Matsuda, Y., Tomii, Y., Tachibana-Kondo, Y., Iikura, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3937 · Cited by 179 · see citing works

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5253 · Cited by 177 · see citing works

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma

Ambrogio, C., Goméz-López, G., Falcone, M., Vidal, A., Nadal, E., Crosetto, N., Blasco, R. B., Fernández-Marcos, P. J., Sánchez‐Céspedes, M., Ren, X., et al. (2016) · Nature Medicine · doi:10.1038/nm.4041 · Cited by 175 · see citing works

What We Have Learned About Pancreatic Cancer From Mouse Models

Pérez-Mancera, P. A., Guerra, C. E., Barbacid, M., & Tuveson, D. A. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.03.002 · Cited by 178 · see citing works

Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer

Shimamura, T., Perera, S. A., Foley, K. P., Sang, J., Rodig, S. J., Inoue, T., Chen, L., Li, D., Carretero, J., Li, Y.-C., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2967 · Cited by 165 · see citing works

RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?

Downward, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2180 · Cited by 162 · see citing works

Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers

Dillon, M., Lopez, A. R., Lin, E., Sales, D., Perets, R., & Jain, P. (2021) · Cancers · doi:10.3390/cancers13205059 · Cited by 175 · see citing works

KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge

Mao, Z., Xiao, H., Shen, P., Yang, Y., Xue, J., Yang, Y., Shang, Y., Zhang, L., Li, X., Zhang, Y., et al. (2022) · Cell Discovery · doi:10.1038/s41421-021-00368-w · Cited by 158 · see citing works

Exploiting the therapeutic implications of KRAS inhibition on tumor immunity

Molina-Arcas, M., & Downward, J. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.012 · Cited by 152 · see citing works

Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model

Xia, Y., Yeddula, N., Leblanc, M., Ke, E., Zhang, Y., Oldfield, E., Shaw, R. J., & Verma, I. M. (2012) · Nature Cell Biology · doi:10.1038/ncb2428 · Cited by 147 · see citing works

Mouse models for lung cancer

Kwon, M.-C., & Berns, A. J. M. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.010 · Cited by 150 · see citing works

Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling

Ponsioen, B., Post, J. B., Amorie, J. R. B. D., Laskaris, D., van Ineveld, R. L., Kersten, S., Bertotti, A., Sassi, F. P., Sipieter, F., Cappe, B., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00654-5 · Cited by 140 · see citing works

Molecular Pathways and Mechanisms of BRAF in Cancer Therapy

Poulikakos, P. I., Sullivan, R. J., & Yaeger, R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2138 · Cited by 145 · see citing works

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

Yen, I., Shanahan, F., Lee, J., Hong, Y. S., Shin, S. J., Moore, A. R., Sudhamsu, J., Chang, M. T., Bae, I., Dela Cruz, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03515-1 · Cited by 138 · see citing works

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future

Uras, I. Z., Moll, H. P., & Casanova, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124325 · Cited by 138 · see citing works

Targeting RAS-mutant cancers: is ERK the key?

Ryan, M. B., Der, C., Wang-Gillam, A., & Cox, A. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.001 · Cited by 125 · see citing works

A Braf kinase-inactive mutant induces lung adenocarcinoma

Nieto, P., Ambrogio, C., Esteban-Burgos, L., Goméz-López, G., Blasco, M. T., Yao, Z., Marais, R., Rosen, N. X., Chiarle, R., Pisano, D. G., et al. (2017) · Nature · doi:10.1038/nature23297 · Cited by 130 · see citing works

New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness

Yang, H., Liang, S.-Q., Schmid, R. A., & Peng, R.-W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00953 · Cited by 129 · see citing works

ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition

Wang, B., Krall, E. B., Aguirre, A. J., Kim, M., Widlund, H. R., Doshi, M. B., Sicińska, E., Sulahian, R., Goodale, A. B., Cowley, G. S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.031 · Cited by 125 · see citing works

MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival

Lee, C.-S., Lee, L. C., Yuan, T. L., Chakka, S., Fellmann, C., Lowe, S. W., Caplen, N. J., McCormick, F., & Luo, J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817494116 · Cited by 126 · see citing works

Therapeutic Effect of γ-Secretase Inhibition in KrasG12V-Driven Non-Small Cell Lung Carcinoma by Derepression of DUSP1 and Inhibition of ERK

Maraver, A., Fernández-Marcos, P. J., Herranz, D., Cañamero, M., Muñoz‐Martín, M., Goméz-López, G., Mulero, F., Megı́as, D., Sänchez‐Carbayo, M., Shen, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.014 · Cited by 120 · see citing works

Alike but Different: RAF Paralogs and Their Signaling Outputs

Desideri, E., Cavallo, A. L., & Baccarini, M. (2015) · Cell · doi:10.1016/j.cell.2015.04.045 · Cited by 119 · see citing works

c-RAF ablation induces regression of advanced Kras/Trp53 mutant lung adenocarcinomas by a mechanism independent of MAPK signaling

Sanclemente, M., Francoz, S., Esteban-Burgos, L., Bousquet-Mur, E., Djurec, M., Lopez-Casas, P. P., Hidalgo, M., Guerra, C., Drosten, M., Musteanu, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.014 · Cited by 119 · see citing works

The genetics and biology of KRAS in lung cancer

Westcott, P. M. K., & To, M. D. (2013) · Chinese Journal of Cancer · doi:10.5732/cjc.012.10098 · Cited by 116 · see citing works

Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors

Montor, W., Salas, A. R. O. S. E., & de Melo, F. H. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0792-2 · Cited by 101 · see citing works

Complete regression of advanced pancreatic ductal adenocarcinomas upon combined inhibition of EGFR and C-RAF

Blasco, M. T., Navas, C., Martín-Serrano, G., Graña-Castro, O., Lechuga, C. G., Martín-Díaz, L., Djurec, M., Li, J., Morales-Cacho, L., Esteban-Burgos, L., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.002 · Cited by 115 · see citing works

Development of siRNA Payloads to Target <i>KRAS</i> -Mutant Cancer

Yuan, T. L., Fellmann, C., Lee, C.-S., Ritchie, C. D., Thapar, V., Lee, L. C., Hsu, D. J., Grace, D., Carver, J. O., Zuber, J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0900 · Cited by 113 · see citing works

Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib

Sen, B., Peng, S., Tang, X., Erickson, H. S., Galindo, H., Mazumdar, T., Stewart, D. J., Wistuba, I. I., & Johnson, F. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003513 · Cited by 111 · see citing works

“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway

Cseh, B., Doma, E., & Baccarini, M. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.06.025 · Cited by 108 · see citing works

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers

Ozkan‐Dagliyan, I., Diehl, J. N., George, S. D., Schaefer, A., Papke, B., Klotz‐Noack, K., Waters, A. M., Goodwin, C. M., Gautam, P., Pierobon, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107764 · Cited by 102 · see citing works

K-Ras protein as a drug target

McCormick, F. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1382-7 · Cited by 105 · see citing works

Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway

Drosten, M., Sum, E. Y. M., Lechuga, C. G., Simón-Carrasco, L., Jacob, H. K. C., García-Medina, R., Huang, S., Beijersbergen, R. L., Bernards, R., & Barbacid, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417549111 · Cited by 103 · see citing works

Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib

Noeparast, M., Teugels, E., Giron, P., Verschelden, G., Brakeleer, S. D., Decoster, L., & Grève, J. D. (2016) · Oncotarget · doi:10.18632/oncotarget.11635 · Cited by 98 · see citing works

Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib

Acquaviva, J., Smith, D. L., Sang, J., Friedland, J. C., He, S., Sequeira, M., Zhang, C., Wada, Y., & Proia, D. A. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0615 · Cited by 96 · see citing works

Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2

Wang, P., Jia, X., Lu, B., Huang, H., Liu, J., Liu, X., Wu, Q., Hu, Y., Li, P., Wei, H., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01329-3 · Cited by 96 · see citing works

Allosteric MEK inhibitors act on BRAF/MEK complexes to block MEK activation

Pino, G. L. G., Li, K., Park, E., Schmoker, A. M., Ha, B. H., & Eck, M. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107207118 · Cited by 95 · see citing works

Synthetic Lethal Vulnerabilities in <i>KRAS</i>-Mutant Cancers

Aguirre, A. J., & Hahn, W. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031518 · Cited by 90 · see citing works

Circulating tumor cells and CDX models as a tool for preclinical drug development

Lallo, A., Schenk, M. W., Frese, K. K., Blackhall, F. H., & Dive, C. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.08.01 · Cited by 89 · see citing works

LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors

Monaco, K., Delach, S. M., Yuan, J., Mishina, Y. M., Fordjour, P., Labrot, E., McKay, D., Guo, R., Higgins, S., Wang, H. Q., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2563 · Cited by 88 · see citing works

Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells

Henry, J. R., Kaufman, M. D., Peng, S.-B., Ahn, Y. M., Caldwell, T. M., Vogeti, L., Telikepalli, H., Lu, W.-P., Hood, M. M., Rutkoski, T. J., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00067 · Cited by 86 · see citing works

ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers

Rebocho, A. P., & Marais, R. (2012) · Oncogene · doi:10.1038/onc.2012.330 · Cited by 83 · see citing works

The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction

Klomp, J. E., Klomp, J. A., & Der, C. J. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200507 · Cited by 84 · see citing works

Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer

Mertens, S., Huismans, M. A., Veríssimo, C. S., Ponsioen, B., Overmeer, R., Proost, N., van Tellingen, O., van de Ven, M., Begthel, H., Boj, S. F., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112324 · Cited by 80 · see citing works

SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers

Jones, G. G., del Río, I. B., Sarı, S., Sekerim, A., Young, L. C., Hartig, N., Zubiaur, I. A., El-Bahrawy, M. A., Hynds, R. E., Lei, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10367-x · Cited by 77 · see citing works

Targeting the MAPK Pathway in RAS Mutant CancersPreprint

Hymowitz, S. G., & Malek, S. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031492 · Cited by 79 · see citing works

The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas

Nussinov, R., Muratcioğlu, S., Tsai, C., Jang, H., Gürsoy, A., & Keskin, Ö. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0165 · Cited by 78 · see citing works

Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors

Yen, I., Shanahan, F., Merchant, M. A., Orr, C., Hunsaker, T., Durk, M. R., La, H., Zhang, X., Martin, S. E., Lin, E., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.09.002 · Cited by 78 · see citing works

MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer

Casacuberta‐Serra, S., González-Larreategui, Í., Capitán-Leo, D., & Soucek, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01907-z · Cited by 83 · see citing works

Impact of context-dependent autophagy states on tumor progression

Assi, M., & Kimmelman, A. C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00546-7 · Cited by 78 · see citing works

Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model

Danysh, B. P., Rieger, E. Y., Sinha, D. K., Evers, C., Cote, G. J., Cabanillas, M. E., & Hofmann, M.-C. C. (2016) · Oncotarget · doi:10.18632/oncotarget.9023 · Cited by 74 · see citing works

Drugging the Undruggable: Advances on RAS Targeting in Cancer

Molina‐Arcas, M., Samani, A., & Downward, J. (2021) · Genes · doi:10.3390/genes12060899 · Cited by 74 · see citing works

Signaling from RAS to RAF: The Molecules and Their Mechanisms

Jeon, H., Tkacik, E., & Eck, M. J. (2024) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-052521-040754 · Cited by 64 · see citing works

Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader

Wei, J., Hu, J., Wang, L., Xie, L., Jin, M. S., Chen, X., Liu, J., & Jin, J. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01528 · Cited by 67 · see citing works

The intermediate-activityL597VBRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathwayPreprint

Andreadi, C., Cheung, L.-K. M., Giblett, S. M., PATEL, B., Jin, H., Mercer, K., Kamata, T., Lee, P., Williams, A. G., McMahon, M., et al. (2012) · Genes & Development · doi:10.1101/gad.193458.112 · Cited by 66 · see citing works

BRAF Mutation Is Associated With a Specific Cell Type With Features Suggestive of Senescence in Ovarian Serous Borderline (Atypical Proliferative) Tumors

Zeppernick, F. A., Ardighieri, L., Hannibal, C. G., VANG, R. S., Junge, J., Kjær, S. K., Zhang, R., Kurman, R. J., & Shih, I. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000313 · Cited by 65 · see citing works

Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration

Mooz, J., Oberoi‐Khanuja, T. K., Harms, G. S., Wang, W., Jaiswal, B. S., Seshagiri, S., Tikkanen, R., & Rajalingam, K. (2014) · Science Signaling · doi:10.1126/scisignal.2005484 · Cited by 64 · see citing works

ERK2 drives tumour cell migration in 3D microenvironments by suppressing expression of Rab17 and Liprin-β2

von Thun, A., Birtwistle, M. R., Kalna, G., Grindlay, J., Strachan, D., Kölch, W., von Kriegsheim, A., & Norman, J. C. (2012) · Journal of Cell Science · doi:10.1242/jcs.092916 · Cited by 64 · see citing works

The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth

Garon, E. B., Finn, R. S., Hamidi, H., Dering, J., Pitts, S. L., Kamranpour, N., Desai, A. J., Hosmer, W., Ide, S. E., Avşar, E., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0998 · Cited by 63 · see citing works

Small Molecule Soluble Epoxide Hydrolase Inhibitors in Multitarget and Combination Therapies for Inflammation and Cancer

Mahapatra, A. D., Choubey, R., & Datta, B. (2020) · Molecules · doi:10.3390/molecules25235488 · Cited by 62 · see citing works

CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment

Tirella, A., Kloc-Muniak, K., Good, L., Ridden, J., Ashford, M., Puri, S., & Tirelli, N. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.02.032 · Cited by 60 · see citing works

The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux

Wiersma, V. R., de Bruyn, M., Wei, Y., van Ginkel, R. J., Hirashima, M., Niki, T., Nishi, N., Zhou, J., Pouwels, S. D., Samplonius, D. F., et al. (2015) · Autophagy · doi:10.1080/15548627.2015.1063767 · Cited by 58 · see citing works

Targeting the prohibitin scaffold-CRAF kinase interaction in RAS-ERK-driven pancreatic ductal adenocarcinoma

Luan, Z., He, Y., Alattar, M., Chen, Z., & He, F. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-38 · Cited by 58 · see citing works

Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer

Pacini, L., Jenks, A. D., Lima, N. C., & Huang, P. H. (2021) · Cells · doi:10.3390/cells10051154 · Cited by 56 · see citing works

Therapeutic inhibition of TRF1 impairs the growth of p53‐deficient K‐RasG12V‐induced lung cancer by induction of telomeric DNA damage

Beccaria, M. G., Martínez, P., Méndez‐Pertuz, M., Martı́nez, S., Blanco‐Aparicio, C., Cañamero, M., Mulero, F., Ambrogio, C., Flores, J. M., Megı́as, D., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404497 · Cited by 57 · see citing works

RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma

Dorard, C., Estrada, C., Barbotin, C., Larcher, M., Garancher, A., Leloup, J., Beermann, F., Baccarini, M., Pouponnot, C., Larue, L., et al. (2017) · Nature Communications · doi:10.1038/ncomms15262 · Cited by 55 · see citing works

TPL2 kinase is a suppressor of lung carcinogenesis

Gkirtzimanaki, K., Gkouskou, K. K., Oleksiewicz, U., Nikolaidis, G., Vyrla, D., Liontos, M., Pelekanou, V., Kanellis, D. C., Evangelou, K., Stathopoulos, E. N., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215938110 · Cited by 54 · see citing works

Deciphering the RAS/ERK pathway in vivo

Dorard, C., Vucak, G., & Baccarini, M. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160135 · Cited by 53 · see citing works

A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies

Liu, Z., Liu, Y., Qian, L., Jiang, S., Gai, X., Ye, S., Chen, Y., Wang, X., Zhai, L., Xu, J. Q., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.07.021 · Cited by 54 · see citing works

Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas

Salmón, M., Álvarez-Díaz, R., Fustero-Torre, C., Brehey, O., Lechuga, C. G., Sanclemente, M., Fernández-García, F., López-García, A., Martín-Guijarro, M. C., Rodríguez-Perales, S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164413 · Cited by 52 · see citing works

Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway inKRAS-mutant non-small cell lung cancer

Haines, E., Chen, T., Kommajosyula, N., Chen, Z., Herter-Sprie, G. S., Cornell, L., Wong, K., & Shapiro, G. I. (2018) · Oncotarget · doi:10.18632/oncotarget.25803 · Cited by 54 · see citing works

ERK1 and ERK2 present functional redundancy in tetrapods despite higher evolution rate of ERK1

Buscà, R., Christen, R., Lovern, M. B., Clifford, A. M., Yue, J., Goss, G. G., Pouysségur, J., & Lenormand, P. (2015) · BMC Evolutionary Biology · doi:10.1186/s12862-015-0450-x · Cited by 51 · see citing works

63 Circulating Metastasis-initiating Cells in Breast Cancer

Baccelli, I., Riethdorf, S., Wallwiener, M., Klein, C., Pantel, K., Weichert, W., Schneeweiß, A., & Trumpp, A. (2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)70767-0

60 Cancer-initiating Cells in Glioblastoma

(2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)70764-5

61 Interactions Between Breast Cancer Stem Cells and their Niche Govern Metastatic Colonization of the Lung

Malanchi, I., Santamaria-Martínez, A., Susanto, E., Peng, H., Lehr, H., Delaloye, J., & Huelsken, J. (2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)70765-7 · Cited by 7 · see citing works

64 Acquired Resistance to Targeted Therapies

(2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)70768-2

62 Proffered Paper: Regression of Metastatic Melanoma by Targeting Melanoma Stem Cells

Abken, H., Schmidt, P., Schlaak, M. S., Hombach, A. A., Bangard, C., Kurschat, P., & Zigrino, P. (2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)70766-9